Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | PRKCA | P17252 | 8/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108966 | 0.92 | PRKCA (0.39) | ALDH1A1PRKCAKMT2AL3MBTL1EPHX2 | |
| SCHEMBL24704071 | 0.88 | KMT2A (0.43) | ALDH1A1KMT2AL3MBTL1KDM4EMAPT | |
| SCHEMBL26000500 | 0.88 | KMT2A (0.43) | ALDH1A1KMT2AL3MBTL1KDM4EMAPT | |
| SCHEMBL26000503 | 0.88 | KMT2A (0.43) | ALDH1A1KMT2AL3MBTL1KDM4EMAPT | |
| SCHEMBL30108872 | 0.84 | ALDH1A1 (0.32) | ALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL30108855 | 0.81 | TP53 (0.42) | ALDH1A1KDM4EMAPT | |
| SCHEMBL30108918 | 0.81 | TSHR (0.34) | ALDH1A1KMT2AL3MBTL1EPHX2MEN1 | |
| SCHEMBL30108940 | 0.78 | CYP2D6 (0.43) | ALDH1A1KMT2AEPHX2KDM4EMEN1 | |
| SCHEMBL30108857 | 0.76 | PRKCA (0.36) | ALDH1A1PRKCAL3MBTL1EPHX2 | |
| SCHEMBL30114958 | 0.72 | KMT2A (0.39) | ALDH1A1KMT2AL3MBTL1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101833-B1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | SHINETSU CHEMICAL CO (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-11731930-B2 | Processes for preparing a (1,2-dimethyl-3-methylenecyclopentyl)acetate compound and (1,2-dimethyl-3-methylenecyclopentyl)acetaldehyde | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230002305-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-4101833-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | Shin-Etsu Chemical Co., Ltd. (JP) | 2022-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731930-B2 | Processes for preparing a (1,2-dimethyl-3-methylenecyclopentyl)acetate compound and (1,2-dimethyl-3-methylenecyclopentyl)acetaldehyde | ADH1C, AKR1C4, AKR1C2 | ALDH1A1 10/4885PRKCA 1640/4885KMT2A 471/4885 |
| US-20230002305-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | ADH1C, AKR1C4, AKR1C2 | ALDH1A1 10/4885PRKCA 1640/4885KMT2A 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.